European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Sökning: WFRF:(Luger A.) > Aletaha D > European League Aga...

1 av 1
Föregående post
Nästa post
Till träfflistan

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies : 2015 update

Gossec, L. (författare): Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), Paris, France & Department of rheumatology, AP-HP, Pitié Salpêtrière Hospital, Paris, France

Smolen, J. S. (författare): Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria & Second Department of Medicine, Hietzing Hospital, Vienna, Austria,Department of Rheumatology, Campus Benjamin Franklin, Charité, Berlin, Germany

Ramiro, S. (författare): Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands

visa fler...

de Wit, M. (författare): EULAR, representing People with Arthritis/Rheumatism in Europe (PARE), London, United Kingdom,European League Against Rheumatism,A.DI.PSO. (Associazione per la Difesa degli Psoriasici)—PE.Pso.POF (Pan European Psoriasis Patients’ Organization Forum), Rome, Italy,Leeds NIHR Musculoskeletal Biomedical Research Unit, LTHT, Leeds, United Kingdom & Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

Cutolo, M. (författare): Research Laboratory and Clinical Division of Rheumatology, Department of Internal Medicine, University of Genova, Viale Benedetto, Italy

Dougados, M. (författare): Medicine Faculty, Paris Descartes University, Paris, France & Rheumatology B Department, APHP, Cochin Hospital, Paris, France

Emery, P. (författare): Leeds NIHR Musculoskeletal Biomedical Research Unit, LTHT, Leeds, United Kingdom & Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

Landewé, R. (författare): Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology Center, Amsterdam, The Netherlands & Atrium Medical Center, Heerlen, The Netherlands,Amsterdam Rheumatology and Immunology Center

Oliver, S. (författare): North Devon, United Kingdom

Aletaha, D. (författare): Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria

Betteridge, N. (författare): EULAR, representing People with Arthritis/Rheumatism in Europe (PARE), London, United Kingdom

Braun, J. (författare): Rheumazentrum Ruhrgebiet, Herne and Ruhr-Universität Bochum, Herne, Germany

Burmester, G. (författare): Department of Rheumatology and Clinical Immunology, Charité—University Medicine Berlin, Germany

Cañete, J. D. (författare): Arthritis Unit, Department of Rheumatology, Hospital Clínic and IDIBAPS, Barcelona, Spain

Damjanov, N. (författare): Belgrade University School of Medicine, Belgrade, Serbia

FitzGerald, O. (författare): Department of Rheumatology, St. Vincent's University Hospital and Conway Institute, University College Dublin, Dublin, Ireland

Haglund, Emma, 1970- (författare): Lund University,Lunds universitet,Högskolan i Halmstad,Bio- och miljösystemforskning (BLESS),Section of Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine

Helliwell, P. (författare): Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom

Kvien, T. K. (författare): Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

Lories, R. (författare): Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center, KU Leuven, Belgium & Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium

Luger, T. (författare): Department of Dermatology, University Hospital Münster, Münster, Germany

Maccarone, M. (författare): A.DI.PSO. (Associazione per la Difesa degli Psoriasici)—PE.Pso.POF (Pan European Psoriasis Patients’ Organization Forum), Rome, Italy

Marzo-Ortega, H. (författare): Leeds NIHR Musculoskeletal Biomedical Research Unit, LTHT, Leeds, United Kingdom & Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

McGonagle, D. (författare): Leeds NIHR Musculoskeletal Biomedical Research Unit, LTHT, Leeds, United Kingdom & Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

McInnes, I. B. (författare): Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom

Olivieri, I. (författare): Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy

Pavelka, K. (författare): Institute and Clinic of Rheumatology Charles University Prague, Czech Republic

Schett, G. (författare): Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany

Sieper, J. (författare): Department of Rheumatology, Campus Benjamin Franklin, Charité, Berlin, Germany

van den Bosch, F. (författare): Ghent University Hospital, Ghent, Belgium

Veale, D. J. (författare): Centre for Arthritis and Rheumatic Disease, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland

Wollenhaupt, J. (författare): Schoen Klinik Hamburg, Rheumatology and Clinical Immunology, Hamburg, Germany

Zink, A. (författare): Department of Rheumatology and Clinical Immunology, German Rheumatism Research Centre Berlin, Charité—University Medicine Berlin, Germany

van der Heijde, D. (författare): Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands

visa färre...

(creator_code:org_t)

2015-12-07
2016
Engelska.
Ingår i: Annals of the Rheumatic Diseases. - London : BMJ Books. - 0003-4967 .- 1468-2060. ; 75:3, s. 499-510

Relaterad länk:: https://doi.org/10.1...; visa fler...; https://ard.bmj.com/...; http://www.ncbi.nlm....; http://dx.doi.org/10...; https://urn.kb.se/re...; https://doi.org/10.1...; https://lup.lub.lu.s...; visa färre...

Tidskriftsartikel (refereegranskat)

Abstract Ämnesord

Stäng

BACKGROUND: Since the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations.METHODS: A systematic literature review was performed regarding pharmacological treatment in PsA. Subsequently, recommendations were formulated based on the evidence and the expert opinion of the 34 Task Force members. Levels of evidence and strengths of recommendations were allocated.RESULTS: The updated recommendations comprise 5 overarching principles and 10 recommendations, covering pharmacological therapies for PsA from non-steroidal anti-inflammatory drugs (NSAIDs), to conventional synthetic (csDMARD) and biological (bDMARD) disease-modifying antirheumatic drugs, whatever their mode of action, taking articular and extra-articular manifestations of PsA into account, but focusing on musculoskeletal involvement. The overarching principles address the need for shared decision-making and treatment objectives. The recommendations address csDMARDs as an initial therapy after failure of NSAIDs and local therapy for active disease, followed, if necessary, by a bDMARD or a targeted synthetic DMARD (tsDMARD). The first bDMARD would usually be a tumour necrosis factor (TNF) inhibitor. bDMARDs targeting interleukin (IL)12/23 (ustekinumab) or IL-17 pathways (secukinumab) may be used in patients for whom TNF inhibitors are inappropriate and a tsDMARD such as a phosphodiesterase 4-inhibitor (apremilast) if bDMARDs are inappropriate. If the first bDMARD strategy fails, any other bDMARD or tsDMARD may be used.CONCLUSIONS: These recommendations provide stakeholders with an updated consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes in PsA, based on a combination of evidence and expert opinion. © 2015 BMJ Publishing Group Ltd & European League Against Rheumatism.

Hitta via bibliotek

Annals of the Rheumatic Diseases (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

1 av 1
Föregående post
Nästa post
Till träfflistan

Hitta mer i SwePub

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Medicinska och f ...; och Samhällsfarmaci ...

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Reumatologi och ...

Artiklar i publikationen: Annals of the Rh ...

Av lärosätet: Högskolan i Halmstad; Lunds universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies : 2015 update

Ämnesord

Nyckelord

Publikations- och innehållstyp

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Sök utanför SwePub